Related references
Note: Only part of the references are listed.Anaplastic large cell lymphoma, ALK-negative
Andres J. M. Ferreri et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Novel TRAF1-ALK Fusion Identified by Deep RNA Sequencing of Anaplastic Large Cell Lymphoma
Andrew L. Feldman et al.
GENES CHROMOSOMES & CANCER (2013)
Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma
Kengo Takeuchi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Anaplastic lymphoma kinase in human cancer
Antonella Barreca et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2011)
Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Sandra E. Ghayad et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2010)
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Alberto M. Martelli et al.
ONCOTARGET (2010)
The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways
Megan S. Lim et al.
BLOOD (2009)
The rapamycin-regulated gene expression signature determines prognosis for breast cancer
Argun Akcakanat et al.
MOLECULAR CANCER (2009)
The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: Results of a phase I study with pharmacokinetics
Ahmad Awada et al.
EUROPEAN JOURNAL OF CANCER (2008)
Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis
L. Gu et al.
LEUKEMIA (2008)
Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy
Rongshi Li et al.
MEDICINAL RESEARCH REVIEWS (2008)
Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
Woo Chul Noh et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
All roads lead to mTOR - Integrating inflammation and tumor angiogenesis
Dung-Fang Lee et al.
CELL CYCLE (2007)
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis
Hendrik Seeliger et al.
CANCER AND METASTASIS REVIEWS (2007)
Pathobiology of ALK+ anaplastic large-cell lymphoma
Hesham M. Amin et al.
BLOOD (2007)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway
M. Marzec et al.
ONCOGENE (2007)
MTOR signalling in human cancer
J. Albanell et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2007)
Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival
Emanuel F. Petricoin et al.
CANCER RESEARCH (2007)
Identification of squamous cell carcinoma associated proteins by proteomics and loss of beta tropomyosin expression in esophageal cancer
Ferdous Rastgar Jazii et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
Francisco Vega et al.
CANCER RESEARCH (2006)
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma
Christopher E. Pelloski et al.
CLINICAL CANCER RESEARCH (2006)
Expression of ALK1 and p80 in inflammatory myofibroblastic tumor and its mesenchymal mimics: A study of 135 cases
MH Cessna et al.
MODERN PATHOLOGY (2002)
ALK+ CD30+ lymphomas:: A distinct molecular genetic subtype of non-Hodgkin's lymphoma
SW Morris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
